B2i Digital

Intelligent Bio Solutions Inc. (NASDAQ: INBS) (Nasdaq: INBS) announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025. Intelligent Bio Solutions is a B2i Digital Featured company. View INBS’s comprehensive profile at https://lnkd.in/gCF9hkFm. The company reported continued progress on its planned U.S. market expansion, revenue growth, and operational efficiency. Commenting on the results, Harry Simeonidis, President & CEO of Intelligent Bio Solutions, stated: “Fiscal 2025 was a pivotal year for our business as we continued to lay the foundation for global growth. We delivered sequential growth over fiscal quarters three and two, driven by increased cartridge revenue, improved operational discipline, and growing international momentum. As we enter fiscal 2026, we’re focused on three strategic priorities: further accelerating growth, advancing operational excellence, and expanding beyond Forensic Use Only settings in the U.S. Our FDA regulatory pathway remains on track, and we are committed to achieving FDA clearance to expand into the U.S., the world’s largest drug screening market, and deliver our non-invasive solution to more organizations seeking fast, dignified, and reliable testing alternatives.” Other highlights from the earnings release included: • Q4 revenue of $843,884, up 16% year-over-year and 16% quarter-over-quarter, with cartridge sales increasing 24% year-over-year. • Active customer base expanded to over 450 accounts across 24 countries, with 115 new accounts added during the fiscal year. • Advanced FDA 510(k) clearance efforts with comprehensive performance data added to submission, including human eccrine sweat testing validation. • Completed multilingual system upgrade supporting Arabic and Latin American Spanish, along with localized websites in Italian, Spanish, and Arabic. See the company’s full earnings release: https://lnkd.in/eTen6KV5. Led by CEO Harry Simeonidis and CFO Spiro Sakiris, INBS is advancing hygienic, rapid, and cost-effective fingerprint sweat-based testing worldwide. The company’s non-invasive, patented technology delivers results in under ten minutes and now supports more than 450 accounts across 24 countries in the workplace safety, law enforcement, drug treatment, and forensics markets. Its experienced global management team includes Anna Turkington, Ghanshyam Poudel, Taylor Doherty, Daniel Brown, Doug Heath, Sugam Pokharel, Victoria Gavrilenko, Rafael da Luz, MBA, Callistus Sequeira, Derek Mapoli MBus, and Peter Passaris. For investor inquiries, visit https://investors.ibs.inc or contact Valter Pinto at INBS@kcsa.com, KCSA Strategic Communications.

Unicycive Therapeutics (Nasdaq: UNCY) announced that the U.S. Patent and Trademark Office granted a new U.S. patent for UNI-494 to treat Chronic Kidney Disease, ensuring intellectual property protection until 2040. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/eg9U-h4f. The new patent follows the issuance of an earlier method of use patent for the treatment of Acute Kidney Injury with UNI-494. Unicycive’s investigational drug essentially works by protecting and restoring the energy-producing components of kidney cells, addressing a root cause of both acute and chronic kidney disease progression. UNI-494 has already received FDA Orphan Drug Designation for the prevention of delayed graft function (DGF) in kidney transplant patients and completed Phase I safety studies. Dr. Shalabh Gupta, MD, CEO of Unicycive, commented, “While we are focused on seeking FDA approval of our lead product oxylanthanum carbonate, we are pleased to announce the issuance of another patent for our second investigational drug, UNI-494. This patent is part of a broader intellectual property portfolio for UNI-494, which supports potential partnership opportunities and future development efforts. We have completed a Phase I clinical study in healthy volunteers and have received Orphan Drug Designation for the prevention of delayed graft function (DGF) in patients undergoing kidney transplantation.” See today’s press release at https://lnkd.in/eDQYWgpX. Unicycive Therapeutics is a clinical-stage biotechnology company developing innovative therapies for kidney diseases. The company’s lead investigational treatment, oxylanthanum carbonate, is a novel phosphate-binding agent for treating hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Its second program, UNI-494, targets conditions related to acute kidney injury and has received FDA orphan drug designation for preventing delayed graft function in kidney transplant patients. Led by CEO Dr. Shalabh Gupta and a seasoned executive team including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, Unicycive is committed to addressing unmet needs in kidney disease treatment. Learn more at Unicycive (https://unicycive.com/) and B2i Digital (https://b2idigital.com/).

The Nuvo Group kicks off an active fall conference season with strategic participation at four major industry events this September, reinforcing its engagement in the capital markets community through sponsorships and long-standing attendance. The Nuvo Group is a B2i Digital Featured Expert. Explore their profile here: https://lnkd.in/e8tSR-uq September 2025 Industry Conferences - 3-4: Gateway Conference, San Francisco, CA (Sponsor) - 3-4: ACG Great Lakes Capital Connection - Grand Rapids, MI - 8-10: Investment Company Institute ETF Conference, Nashville, TN - 16-17: National Investment Banking Association (NIBA) Annual Conference, Fort Lauderdale, FL (Sponsor) The Nuvo Group team looks forward to connecting with clients and colleagues at these events. To schedule a meeting or learn more about their comprehensive suite of services, reach out directly to Scott Lam. Led by Managing Partners Tony Barletta and Fred Jaffe, The Nuvo Group continues to serve public companies, investment banks, and law firms with accuracy, compliance expertise, and a commitment to making regulatory processes more efficient. For updates on The Nuvo Group and other Featured Experts, visit B2i Digital: https://lnkd.in/em26xtFZ.

Kolibri Global Energy Inc. (Nasdaq: KGEI, TSX: KEI) reported Q2 2025 production averaging 3,220 BOEPD, a 3% increase year-over-year, and anticipates substantially higher production from 9 new wells coming online in H2 2025. Kolibri Global Energy Inc. is a B2i Digital Featured Company. View their complete profile at https://lnkd.in/eVHcxRGp and follow Kolibri on X, Facebook, and LinkedIn. Highlights of today’s operations update include: - Q2 2025 average production increased to 3,220 BOEPD despite 540 BOEPD reduction from wells temporarily shut-in (halted) during Lovina completion operations. - Generated Adjusted EBITDA of $7.7 million in Q2 2025. - Lovina Wells began production in late July with a 4-day average production ranging from 322 to 643 BOEPD, producing a higher oil percentage than many previous wells. - Company repurchased over 207,000 shares from April-July 2025 at an average price of $6.42/share, bringing total repurchases to 504,000+ shares since September 2024. - Production and operating expenses decreased to $7.15 per BOE in Q2 2025 vs. $8.48 per BOE in Q2 2024. In today’s news release Wolf Regener, President and CEO, commented, “We are pleased that the Company’s wells continued to perform well with average production of 3,220 boepd despite a 540 boepd reduction due to several wells that were temporarily shut-in during the quarter for the Lovina wells completion. The wells are producing a higher percentage of oil than many of our previous wells, and we are running production tubing strings this week, which could lead to higher production based on our past experience.” See the full news release at: https://lnkd.in/eddJYpxq Kolibri is led by Wolf Regener, President and CEO, alongside a seasoned technical team including CFO Gary Johnson, CPA, MBA, Director of Engineering Dan Simpson, Senior Geologist Allan Hemmy, and Landman Dalia Isaac. The company is focused on developing its oil-rich Caney acreage in Oklahoma. For additional details, please visit Kolibri’s website at: https://kolibrienergy.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted KGEI stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of KGEI or any security, and it is not intended to offer any opinion on KGEI as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m.

New Insights from Vycor Medical, Inc. (OTCQB: VYCO) on Advancing Minimally Invasive Brain Surgery Vycor Medical, Inc. is a B2i Digital Featured Venture Company. See the complete profile at https://lnkd.in/eZxxWBVU A recent clinical study highlights how tubular retractors—especially the neurosurgeon-designed ViewSite Brain Access System (VBAS)—are transforming cranial surgery by enabling complex procedures through smaller openings with less disruption to brain tissue. With over 45 peer-reviewed studies documenting reduced operating room time, shorter ICU stays, and improved patient outcomes, VBAS represents a major advancement in minimally invasive neurosurgery. This technology builds on the evolution from traditional large craniotomies to keyhole approaches, now offering deep lesion access with less trauma and greater safety. Read the full article here: https://lnkd.in/ennNK9YA #MinimallyInvasiveSurgery #NeurosurgeryInnovation #BrainSurgery #NeuroTechnology #MedicalDevices #VBAS #VycorMedical #SurgicalInnovation #PatientOutcomes #B2iDigital

Spartan Capital Securities, LLC and B2i Digital are pleased to announce that United States Antimony Corporation (NYSE American, NYSE Texas: UAMY) will be a presenting company at the upcoming Spartan Capital Investor Conference on November 3rd, 2025, in New York. The Spartan Capital Investor Conference 2025 is a B2i Digital Featured Conference, and United States Antimony Corporation is a B2i Digital Featured Company. A UAMY company profile is available at https://lnkd.in/e4zC5F_v. Now in its second year, the Spartan Capital Investor Conference brings together public company executive teams, institutional investors, and thought leaders from across the U.S. capital markets for strategic networking and information exchange. Taking place on November 3rd, 2025, at the Marriott Marquis Hotel in New York, this premier event will welcome 500+ institutional and high-net-worth investors and feature presentations from 50 public and private growth companies across technology, healthcare, consumer, and other high-opportunity sectors. Event details and registration are available at https://lnkd.in/edsVSMsh. B2i Digital is working closely with the outstanding Spartan Capital team, including John D. Lowry (CEO), Kim Monchik (CAO), Stephen Faucetta (Director), and Julia Voss (Executive Assistant), to enhance each presenter’s reach through in-depth digital profiles and targeted outreach. Investors can register to attend: https://lnkd.in/g8Y249nF. United States Antimony Corporation is advancing critical mineral production and strategic metal supply chains under the leadership of Chairman and CEO Gary C. Evans, a transformational leader and serial entrepreneur who has taken three separate energy companies public on the NYSE and raised over $8 billion in various forms of capital throughout his career. The company’s experienced executive team includes top industry professionals such as Joe Bardswich (EVP & Chief Mining Officer), John C. Gustavsen (President of Antimony Division), Richard R. Isaak (SVP & CFO), Melissa M. Pagen (SVP of Corporate Development & Government Relations), Aaron Tenesch (VP of Antimony Division), Jonathan Miller (VP of Investor Relations & Global Sales Manager), Leo Jackson (VP of Mexico Antimony Operations), Rodney Blakestad, J.D., C.P.G. (VP of Mining Division), and Rebecca Gower (Assistant VP-Geologist, Mining Division). The company’s focused approach on antimony, zeolite, and precious metals production from operations in Montana, Idaho, and Mexico aims to deliver essential materials for flame-retardant, battery, ordnance, specialty-chemical, and environmental applications. Learn more about United States Antimony Corporation at https://www.usantimony.com. For investor inquiries, contact Jonathan Miller, VP Investor Relations, at jmiller@usantimony.com.

Chris Donaghey, CEO of Applied Energetics, Inc. (OTCQB: AERG), a specialist in ultrashort pulse laser technology and advanced directed energy solutions, issued a letter to shareholders outlining the company’s strategic progress and technical achievements in the first half of 2025. Applied Energetics is a B2i Digital Featured Company. View its profile at https://lnkd.in/eVEkcBCH. Among the highlights from his letter: - The company exceeded peak power performance targets in live system testing for its PLAID™-L (Pulsed Lethality for Air Defense - Low Altitude) program. - Expanded engineering team and upgraded facilities are enabling faster development cycles and broader platform integration capabilities. - Growing demand signals from U.S. and allied defense organizations for systems countering Group 1-2 UAS and electro-optic sensors. - Recently secured nearly $3 million in paid-in capital to support growth initiatives, including testing expansion, personnel growth, and potential uplisting to a national stock market. Donaghey’s letter also noted, “Our mission extends beyond technology development - we are committed to redefining how directed energy is deployed to safeguard national security and ultimately achieving our vision statement: Directed Energy, Anywhere™.” See the full release at: https://lnkd.in/e7sB2X9j. Applied Energetics continues to leverage its portfolio of 27 issued patents and 7 pending patents to advance next-generation defense and dual-use applications, especially fiber-based ultrashort pulse (USP) laser technologies. Learn more about Applied Energetics: https://lnkd.in/eP5rbxAG. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted AERG stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of AERG or any security, and it is not intended to offer any opinion on AERG as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m

Unicycive Therapeutics (Nasdaq: UNCY) announced its financial results for the three months ended June 30, 2025, and provided a business update. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/eg9U-h4f. Among the highlights of today’s announcement are: • Unicycive has requested a Type A meeting with U.S. Food and Drug Administration (FDA) to discuss resolution of the Complete Response Letter for oxylanthanum carbonate (OLC). • OLC pivotal study data published in the Clinical Journal of the American Society of Nephrology (CJASN) demonstrated well-tolerated treatment enabling serum phosphate control in over 90% of patients with low pill burden. • The company ended Q2 with $22.3 million of cash, and an expected runway into the second half of 2026. • Type A meetings are typically granted by FDA within 30 days of request, with company planning an investor update in Q3 2025, after receiving FDA written feedback. Dr. Shalabh Gupta, MD, CEO of Unicycive, commented, “Our team has made great progress in the second quarter, and we have requested a Type A meeting with the FDA to resolve the CRL and obtain regulatory approval. We believe we have built multiple approaches to correct the deficiency noted for our third-party manufacturing vendor, which was unrelated to OLC. Meanwhile, the recently published pivotal trial data in CJASN continue to highlight OLC’s best-in-class potential. Given the high rates of patient non-compliance with existing phosphate lowering therapies, we remain fully committed to meeting this clear need for improved treatment options for managing hyperphosphatemia in dialysis patients.” See today’s press release at https://lnkd.in/emZmhBVb Unicycive Therapeutics is a clinical-stage biotechnology company developing innovative therapies for kidney diseases. The company’s lead investigational treatment, oxylanthanum carbonate, is a novel phosphate-binding agent for treating hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Its second program, UNI-494, targets conditions related to acute kidney injury and has received FDA orphan drug designation for preventing delayed graft function in kidney transplant patients. Led by CEO Dr. Shalabh Gupta and a seasoned executive team including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, Unicycive is committed to addressing unmet needs in kidney disease treatment. Learn more at Unicycive (https://unicycive.com/) and B2i Digital (https://b2idigital.com/).

What does the recent CRL news mean for Unicycive? It means we’re as focused as ever on bringing our potential best-in-class treatment for hyperphosphatemia to market as soon as possible. Hear more from our CEO Shalabh Gupta, MD, and find additional details in our Q2 earnings: http://bit.ly/3JlxuIt

United States Antimony Corporation (NYSE American, NYSE Texas: UAMY) announced second-quarter and six-month financial and operational results for the period ended June 30, 2025, with Revenues up 160%, Gross Profit up 183%, and Net Income up 707%, respectively, YOY. US Antimony Corporation (USAC) is a B2i Digital Featured Company. The company’s comprehensive investor profile is at: https://lnkd.in/e4zC5F_v. Highlights from the company’s announcement include: • Record Financial Performance: Six-month revenues increased to $17.53 million (up 160% YOY), with gross profit rising 183% to $5.21 million. • Operational Turnaround: Company successfully resolved supply chain challenges and staffing issues that impacted Q2 performance. • Production Expansion: Retrofitted four furnaces at Thompson Falls facility ($300K investment) to enable doubling of antimony production output. • Strategic Inventory Position: Antimony International inventories are at record levels, positioning the company for enhanced production capacity. • Mining Development: Expansion efforts at Thompson Falls on schedule for year-end completion, with final mining permits pending for Alaska and Montana projects. • Market Positioning: CEO Evans noted that 6.5% antimony-bearing rock has approximately the same value as one ounce per ton of gold at current metal prices, calling antimony “the New Gold.” Commenting on the Second Quarter and Six Months Ended June 30, 2025, financial and operational results, Mr. Gary C. Evans, Chairman and CEO of US Antimony Corporation, stated, “While we reported today another record quarter and first six months financial results, it could have been a lot better. Evans continued, “Our current antimony international inventories are at record levels as can be seen on our balance sheet. We successfully retrofitted four existing furnaces in Thompson Falls at a cost of approximately $300K over the last few months. This will enable us to begin doubling production output of antimony products now that we have the necessary plant personnel in place.” To read the full news release, visit: https://lnkd.in/e25Ne7Zz. For investor inquiries, contact Jonathan Miller, VP Investor Relations, at jmiller@usantimony.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UAMY stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of UAMY or any security, and it is not intended to offer any opinion on UAMY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m.